Your browser doesn't support javascript.
loading
Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-K. pneumoniae in Febrile Neutropenic Patients with Acute Leukemia Who are Colonized with KPC-K. pneumoniae. A 7-Years Retrospective Observational Cohort Study.
Micozzi, Alessandra; Minotti, Clara; Capria, Saveria; Cartoni, Claudio; Trisolini, Silvia Maria; Assanto, Giovanni Manfredi; Barberi, Walter; Moleti, Maria Luisa; Santilli, Stefania; Martelli, Maurizio; Gentile, Giuseppe.
Afiliación
  • Micozzi A; Haematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Minotti C; Department of Haematology, Oncology and Dermatology, Azienda Policlinico Umberto I, Rome, Italy.
  • Capria S; Department of Haematology, Oncology and Dermatology, Azienda Policlinico Umberto I, Rome, Italy.
  • Cartoni C; Department of Haematology, Oncology and Dermatology, Azienda Policlinico Umberto I, Rome, Italy.
  • Trisolini SM; Department of Haematology, Oncology and Dermatology, Azienda Policlinico Umberto I, Rome, Italy.
  • Assanto GM; Haematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Barberi W; Department of Haematology, Oncology and Dermatology, Azienda Policlinico Umberto I, Rome, Italy.
  • Moleti ML; Department of Haematology, Oncology and Dermatology, Azienda Policlinico Umberto I, Rome, Italy.
  • Santilli S; Department of Diagnostics, Azienda Policlinico Umberto I, Rome, Italy.
  • Martelli M; Haematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Gentile G; Haematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Infect Drug Resist ; 16: 695-704, 2023.
Article en En | MEDLINE | ID: mdl-36747900
ABSTRACT

Purpose:

To evaluate the benefits and safety of the empiric antibiotic treatment (EAT) active against KPC-K. pneumoniae in febrile neutropenic patients with acute leukaemia (AL) who are colonised by KPC-K. pneumoniae. Patients and

Methods:

A 7-year (2013-2019) retrospective observational cohort study was conducted at the Haematology, Sapienza Rome University (Italy) on 94 febrile neutropenia episodes (FNE) in AL patients KPC-K. pneumoniae carriers treated with active EAT.

Results:

Eighty-two (87%) FNE were empirically treated with antibiotic combinations [38 colistin-based and 44 ceftazidime-avibactam (CAZAVI)-based], 12 with CAZAVI monotherapy. Successful outcomes were observed in 88/94 (94%) FNE, 46/49 (94%) microbiologically documented infections, and 24/27 (89%) gram-negative bloodstream infections (GNB-BSI). Mortality due to infective causes was 4.2% (2.1% within 1 week). KPC-K. pneumoniae infections caused 28/94 FNE (30%) and KPC-K. pneumoniae-BSI was documented in 22 FNE (23.4%) (85% of GNB-BSI), in all cases patients received active EAT, and 21 survived. KPC-K.pneumoniae-BSI mortality rate was 4.5%. CAZAVI-based EAT showed better results than colistin-based EAT (55/56 vs 33/38, p = 0.037), overall and without EAT modification (41/56 vs 20/38, p = 0.02). Empirical combinations including CAZAVI were successful in 98% of cases (43/44 vs 33/38 for colistin-based EAT, p = 0.01), without modifications in 82% (36/44 vs 20/28, p = 0.02). All deaths occurred in patients treated with colistin-based EAT (4/38 vs 0/56, p = 0.02). CAZAVI-containing EAT was the only independent factor for an overall successful response (HR 0.058, CI 0.013-1.072, p = 0.058). Nephrotoxicity occurred in 3(8%) patients undergoing colistin-based EAT (none in those undergoing CAZAVI-based EAT, p = 0.02).

Conclusion:

KPC-K. pneumoniae infections are frequent in colonised AL patients with FNE. EAT with active antibiotics, mainly CAZAVI-based combinations, was effective, safe, and associated with low overall and KPC-K. pneumoniae-BSI-related mortality.
Palabras clave

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Infect Drug Resist Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Infect Drug Resist Año: 2023 Tipo del documento: Article País de afiliación: Italia